03.25.14
Insulet Corporation has appointed Patrick Ryan as the company's chief operating officer (COO).
Ryan, a global supply chain expert and seasoned medical device executive, most recently served as COO and president, International, of Alphatec Spine Inc., where he was responsible for Manufacturing & Supply Chain, Research & Development, Clinical, Regulatory & Quality and International Sales & Operations.
"Pat is a proven leader with an exceptional track record of global accomplishments and we are excited to add his expertise to the team," Insulet President/CEO Duane DeSisto. "With strong demand for the new, smaller OmniPod, Pat's many years of success overseeing supply chain management will be a valuable asset. His operational expertise will be instrumental as we further expand manufacturing capacity to support the growing customer base for our tubeless insulin pump."
From 2006 to 2011, Ryan worked at Abbott Vascular in key roles such as divisional vice president, North Asia and divisional vice president, Canada and Latin America. Previously, he held senior roles in operations at Abbott Vascular, including divisional vice president, Worldwide Operations and divisional vice president, Operations, Cardiac Therapies. Prior to Abbott Vascular, Ryan served in numerous leadership positions at Guidant Corporation from 1997 to 2006, including vice president and managing director, Guidant Ireland. Before his career in the medical device industry, Ryan served in the U.S. Navy for 14 years. Ryan received a B.S. in Economics from the United States Naval Academy and a M.S. in Petroleum Management from the University of Kansas.
Ryan succeeds Charles Liamos, who served as Insulet's COO since 2010. Liamos will continue to serve as a member of Insulet's board of directors, a role he has held since 2005.
"I'd like to personally thank Charlie for his efforts and dedication over the last three years. His willingness to step into an executive position from the board of directors and provide invaluable leadership, guidance and expertise to our operations teams was critical to our ability to convert our manufacturing capabilities to the new OmniPod," said DeSisto. "With capacity to produce approximately 1 million OmniPods per month across three manufacturing lines and a fourth line scheduled to be qualified later this year, Charlie determined this was the right time to step back into an advisory role."
Insulet Corporation developed the all-in-one tubeless insulin pump. The 14-year-old company is based in Bedford, Mass.
Ryan, a global supply chain expert and seasoned medical device executive, most recently served as COO and president, International, of Alphatec Spine Inc., where he was responsible for Manufacturing & Supply Chain, Research & Development, Clinical, Regulatory & Quality and International Sales & Operations.
"Pat is a proven leader with an exceptional track record of global accomplishments and we are excited to add his expertise to the team," Insulet President/CEO Duane DeSisto. "With strong demand for the new, smaller OmniPod, Pat's many years of success overseeing supply chain management will be a valuable asset. His operational expertise will be instrumental as we further expand manufacturing capacity to support the growing customer base for our tubeless insulin pump."
From 2006 to 2011, Ryan worked at Abbott Vascular in key roles such as divisional vice president, North Asia and divisional vice president, Canada and Latin America. Previously, he held senior roles in operations at Abbott Vascular, including divisional vice president, Worldwide Operations and divisional vice president, Operations, Cardiac Therapies. Prior to Abbott Vascular, Ryan served in numerous leadership positions at Guidant Corporation from 1997 to 2006, including vice president and managing director, Guidant Ireland. Before his career in the medical device industry, Ryan served in the U.S. Navy for 14 years. Ryan received a B.S. in Economics from the United States Naval Academy and a M.S. in Petroleum Management from the University of Kansas.
Ryan succeeds Charles Liamos, who served as Insulet's COO since 2010. Liamos will continue to serve as a member of Insulet's board of directors, a role he has held since 2005.
"I'd like to personally thank Charlie for his efforts and dedication over the last three years. His willingness to step into an executive position from the board of directors and provide invaluable leadership, guidance and expertise to our operations teams was critical to our ability to convert our manufacturing capabilities to the new OmniPod," said DeSisto. "With capacity to produce approximately 1 million OmniPods per month across three manufacturing lines and a fourth line scheduled to be qualified later this year, Charlie determined this was the right time to step back into an advisory role."
Insulet Corporation developed the all-in-one tubeless insulin pump. The 14-year-old company is based in Bedford, Mass.